{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:50:04Z","timestamp":1767142204854,"version":"build-2238731810"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ck0106616h0001"],"award-info":[{"award-number":["20ck0106616h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ck0106482h0002"],"award-info":[{"award-number":["20ck0106482h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12185-021-03102-0","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T05:05:34Z","timestamp":1613711134000},"page":"861-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia\/lymphoma"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-7616","authenticated-orcid":false,"given":"Nobuaki","family":"Nakano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifusa","family":"Takatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Miyazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Odawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torahiko","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikiyo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"3102_CR1","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult t-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458\u201364.","journal-title":"J Clin Oncol"},{"key":"3102_CR2","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"Bazarbachi A, Plumelle Y, Ramos JC, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177\u201383.","journal-title":"J Clin Oncol"},{"key":"3102_CR3","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","volume":"30","author":"H Katsuya","year":"2012","unstructured":"Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol. 2012;30:1635\u201340.","journal-title":"J Clin Oncol"},{"key":"3102_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group. Br J Haematol. 1991;79:428\u201337.","journal-title":"Br J Haematol"},{"key":"3102_CR5","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/cas.13398","volume":"108","author":"K Nosaka","year":"2017","unstructured":"Nosaka K, Iwanaga M, Imaizumi Y, Ishitsuka K, Ishizawa K, Ishida Y, et al. Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010\u20132011: a nationwide survey. Cancer Sci. 2017;108:2478\u201386.","journal-title":"Cancer Sci"},{"key":"3102_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","volume":"27","author":"A Utsunomiya","year":"2001","unstructured":"Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, et al. Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:15\u201320.","journal-title":"Bone Marrow Transplant"},{"key":"3102_CR7","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","volume":"116","author":"M Hishizawa","year":"2010","unstructured":"Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369\u201376.","journal-title":"Blood"},{"key":"3102_CR8","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","volume":"120","author":"T Ishida","year":"2012","unstructured":"Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734\u201341.","journal-title":"Blood"},{"key":"3102_CR9","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/bmt.2014.143","volume":"49","author":"A Bazarbachi","year":"2014","unstructured":"Bazarbachi A, Cwynarski K, Boumendil A, Finel H, Fields P, Raj K, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant. 2014;49:1266\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3102_CR10","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.bbmt.2014.08.012","volume":"20","author":"K Kato","year":"2014","unstructured":"Kato K, Choi I, Wake A, Uike N, Taniguchi S, Moriuchi Y, et al. Treatment of patients with adult T cell leukemia\/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey. Biol Blood Marrow Transplant. 2014;20:1968\u201374.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3102_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s12185-012-1177-8","volume":"96","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Oku E, Nomura K, Morishige S, Takata Y, Seki R, et al. Unrelated cord blood transplantation for patients with adult T-cell leukemia\/lymphoma: experience at a single institute. Int J Hematol. 2012;96:657\u201363.","journal-title":"Int J Hematol"},{"key":"3102_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s12185-013-1307-y","volume":"97","author":"T Fukushima","year":"2013","unstructured":"Fukushima T, Itonaga H, Moriuchi Y, Yoshida S, Taguchi J, Imaizumi Y, et al. Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia\/lymphoma: a retrospective analysis of the Nagasaki Transplantation Network. Int J Hematol. 2013;97:485\u201390.","journal-title":"Int J Hematol"},{"key":"3102_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.bbmt.2008.02.016","volume":"14","author":"ME Horwitz","year":"2008","unstructured":"Horwitz ME, Morris A, Gasparetto C, Sullivan K, Long G, Chute J, et al. Myeloablative intravenous busulfan\/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant. 2008;14:591\u20134.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3102_CR14","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.bbmt.2016.06.017","volume":"22","author":"H Yamamoto","year":"2016","unstructured":"Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kajiet D, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transplant. 2016;22:1844\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"3102_CR15","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/sj.leu.2404886","volume":"21","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine\/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine\/busulfan. Leukemia. 2007;21(10):2109\u201316.","journal-title":"Leukemia"},{"issue":"7","key":"3102_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/cncr.29163","volume":"121","author":"F Baron","year":"2015","unstructured":"Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, et al. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2015;121(7):1048\u201355.","journal-title":"Cancer"},{"issue":"8","key":"3102_CR17","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.bbmt.2016.04.026","volume":"22","author":"M Damlaj","year":"2016","unstructured":"Damlaj M, Alkhateeb HB, Hefazi M, Partain DK, Hashmi S, Gastineau DA, et al. Fludarabine-busulfan reduced-intensity conditioning in comparison with fludarabine-melphalan is associated with increased relapse risk in spite of pharmacokinetic dosing. Biol Blood Marrow Transplant. 2016;22(8):1431\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"3102_CR18","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/bloodadvances.2018021980","volume":"2","author":"M Eapen","year":"2018","unstructured":"Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM, et al. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018;2(16):2095\u2013103.","journal-title":"Blood Adv"},{"key":"3102_CR19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"393","key":"3102_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"19","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;19(393):229\u201340.","journal-title":"Lancet"},{"key":"3102_CR21","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426\u201333.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s12185-021-03125-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03102-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03102-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03102-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T07:26:29Z","timestamp":1627629989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03102-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["3102"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03102-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"5 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-021-03125-7","URL":"https:\/\/doi.org\/10.1007\/s12185-021-03125-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}